Business Information
The group's principal activities are the research and development, manufacture and sale of prescription pharmaceutical products. The group's five platform technologies are oral, injectable, inhalation, topical and solubilisation. Products include Paxil CR, Xatral OD, Uroxatral, Madopar DR, Coruno, Nifedipine, Diclofenac, Requip, Zileuton, Statin NK - 104, Altace, Foradil, Certihaler, Pulmicort HFA, Formoterol HFA, Qab 149, Formoterol Combi, Depocyt, Depomorphine, Psoraxine, Depobupivacaine, HGH, Interferon Alpha-2B, Solaraze, Multiple, Fenofibrate, Propofol IDD-D, and Busulfan.
|
|
Name |
Title
|
Email
|
| Frank Condella | CEO | N/A | | Ken Cunningham | COO | N/A | | Lorraine Jones | Head - Business Development | Available | | Alan Bray | Dir. | N/A | | Argeris Karabelas | Non Exec. Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2005 | 105,485 | (84,663) | | 2004 | 119,773 | (40,010) | | 2003 | 129,233 | (65,954)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
